3:24 PM
 | 
Nov 07, 2018
 |  BC Extra  |  Company News

Management tracks: Myovant, Alkahest

Women’s health and endocrine disease company Myovant Sciences Ltd. (NYSE:MYOV) named Kim Sablich chief commercial officer and Jeff Nornhold SVP of pharmaceutical operations and development. Sablich was VP of primary care marketing in the U.S. for GlaxoSmithKline plc (LSE:GSK; NYSE:GSK), and Nornhold was SVP of technical operations for Impax Laboratories Inc. Impax merged with Amneal Pharmaceuticals LLC in May to form generics company Amneal Pharmaceuticals Inc. (NYSE:AMRX).

Age-related disease company Alkahest Inc. (San Carlos, Calif.) hired Elizabeth Jeffords as chief commercial and strategy officer. She was VP of the U.S. ophthalmology portfolio of the Genentech Inc. unit of Roche (SIX:ROG; OTCQX:RHHBY).

CNS disorder company Impel NeuroPharma Inc. (Seattle, Wash.) hired Ellen Lubman as CBO, a new position according to CEO Jon Congleton. She was VP of external science and innovation at Allergan plc (NYSE:AGN).

Progressive kidney disease company Xortx Therapeutics Inc. (CSE:XRX; OTCQB:XRTXF) hired James Fairbairn as CFO. He succeeds Dave Matthews, who was named Xortx CFO in February. Fairbairn was recently CFO at Metanor Resources Inc.; Canadian gold exploration company Bonterra Resources Inc. (TSX-V:BTR; OTCQX:BONXD) acquired Metanor in September.

RNAi company Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY) promoted VP of Commercial Operations Andy Orth to SVP, Head of U.S. and hired Norton Oliveira as SVP, head of Latin America, a newly created position according to Alnylam spokesperson Christine Lindenboom. Oliveira was VP for Latin America and the Caribbean at Gilead Sciences Inc. (NASDAQ:GILD).

Population-based genomics company Genomics Medicine Ireland Ltd. (Dublin, Ireland) named Anne Jones CEO. Dan Crowley has been acting CEO since co-founding the company in 2015. Jones was VP and general manager for the Pall Corp. Lab, Food and Beverage business at Danaher Corp. (NYSE:DHR).

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

Purchase this article for limited one-time distribution and website posting

$750 USD